ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

PartnershipPositive

AI Analysis

Summary

Allogene Therapeutics (ALGS) stock rallied 16% after-hours following a $25M cash payment from a China-based hepatitis B drug deal. The partnership provides near-term funding for the company's pipeline.

Outcome Details

$25M cash payment from China hepatitis B drug deal

Importance:6/10

Sentiment:

0.85

partnershipcash_infusionhepatitis_bchinastock_rally

Related Companies

$ALGS

Read the original article

Published by yahoo_finance on July 6, 2026 11:50 PM

Read Original